HIBERIX 10 MCG / 0.5 ML
HAEMOPHILUS INFLUENZAE TYPE B-PRP AND TETANUS TOXOID CONJUGATE (PRP-T) : 10 MCG / 0.5 ML · DIN 02239200 · GLAXOSMITHKLINE INC
Health Canada status: CANCELLED POST MARKET
What is HIBERIX?
HIBERIX 10 MCG / 0.5 ML contains HAEMOPHILUS INFLUENZAE TYPE B-PRP AND TETANUS TOXOID CONJUGATE (PRP-T) : 10 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02239200, held by GLAXOSMITHKLINE INC, supplied as POWDER FOR SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 12-Apr-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HIBERIX used for?
HIBERIX is indicated for active immunization of all infants from the age of 2 months against disease caused by Hib. It does not prevent against disease due to other types of H. influenzae nor against meningitis caused by other organisms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02239200 |
|---|---|
| Brand name | HIBERIX |
| Generic / active ingredient | HAEMOPHILUS INFLUENZAE TYPE B-PRP AND TETANUS TOXOID CONJUGATE (PRP-T) : 10 MCG / 0.5 ML |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 10 MCG / 0.5 ML |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07AG51 HEMOPHILUS INFLUENZAE B, COMBINATIONS WITH TOXOIDS |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 12-Apr-2023 |
| Original market date | 2012-10-25 00:00:00 |
How is it stored and handled?
The lyophilized Hib vaccine must be stored at 2°C to 8°C. The lyophilized vaccine is not affected by freezing. Do not use beyond the expiry date printed on the label. The sterile diluent can be stored in the refrigerator (2°C to 8°C) or at ambient temperatures (up to 25°C). DO NOT FREEZE DILUENT.
How is it supplied?
Monopack (1 vaccine dose per pack: 1 vial of lyophilized vaccine/1 prefilled syringe with diluent)
What can be used instead?
Other Canadian products sharing ATC code J07AG51 HEMOPHILUS INFLUENZAE B, COMBINATIONS WITH TOXOIDS. 0 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HIBTITER SOL INJ | 10 MCG / 0.5 ML | LIQUID | PRAXIS BIOLOGICS INC. | CANCELLED POST MARKET | DIN 01943146 |
| PROHIBIT INJ VACCINE | 25 MCG / 0.5 ML | LIQUID | AVENTIS PASTEUR LIMITED | CANCELLED POST MARKET | DIN 00764221 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.